Hikma launches Fidaxomicin Tablets as Hikma stock expands US portfolio

Published on 10/20/2026 at 13:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma launched 200mg Fidaxomicin Tablets in the US on October 15, 2026. Hikma stock costs EUR 19.97 on October 20, 2026 at Lang & Schwarz.

Launch and analyst context

Hikma launched 200mg Fidaxomicin Tablets in the United States on October 15, 2026.
Citi cut its Hikma target from GBp 1,870 to GBp 1,810 on October 13, 2026.
Hikma stock trades at EUR 19.97 at 1:06 p.m. CEST at Lang & Schwarz on October 20, 2026.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma (ISIN GB00B0LCW083) launched 200mg Fidaxomicin Tablets in the United States on October 15, 2026. The product expands the company's US portfolio for adults with Clostridioides difficile-associated diarrhea, according to Hikma.

What does the launch add?

The 200mg tablet gives Hikma another non-injectable product for the US market, where the company operates a manufacturing facility in Columbus, Ohio. The launch also keeps attention on the portfolio strategy described in Hikma's investor materials, which groups the business into Injectables, Branded and Hikma Rx segments.

The Fidaxomicin release identifies US manufacturing as part of the product's positioning. It also states that the medicine received US Food and Drug Administration approval for marketing in the United States, while the release names no authorization for other markets.

Why the product matters

Hikma's investor-relations page says the interim results covered the six months ended June 30, 2026 and were released on August 6, 2026. The company said it reiterated its full-year 2026 guidance and reported 15 percent first-half revenue growth in Branded, according to Hikma.

Analyst attention has been more cautious. Citi maintained a Buy rating but set a GBp 1,810 target on October 13, 2026, down from GBp 1,870, as reported by Markets Insider. That target revision provides a quantified counterpoint to the latest product expansion.

Stock quote and valuation

Hikma's LSE quote was GBp 1,667.00 at 12:09 p.m. CEST on October 20, 2026. The same quote showed a 52-week range of GBp 1,187.00 to GBp 1,865.00 and market capitalization of GBP 3.5 billion, placing the share 10.61 percent below its yearly high.

At Lang & Schwarz, Hikma stock was trading at EUR 19.97 on October 20, 2026 at 1:06 p.m. CEST. The product launch, the interim reporting period and the Citi target revision give investors three separate reference points for assessing the stock's next update.

The further course of trading is shown by the continuously updated real-time quote of Hikma stock.